These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
315 related items for PubMed ID: 9557932
21. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753 [Abstract] [Full Text] [Related]
22. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Tikkanen I, Omvik P, Jensen HA. J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133 [Abstract] [Full Text] [Related]
23. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, Remuzzi G. Am J Physiol; 1999 Mar; 276(3):F457-66. PubMed ID: 10070170 [Abstract] [Full Text] [Related]
24. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA. Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385 [Abstract] [Full Text] [Related]
25. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Fridman K, Wysocki M, Friberg P, Andersson OK. Am J Hypertens; 2000 Sep; 13(9):1045-8. PubMed ID: 10981559 [Abstract] [Full Text] [Related]
26. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L, Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098 [Abstract] [Full Text] [Related]
27. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. von zur Mühlen B, Kahan T, Hägg A, Millgård J, Lind L. J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101 [Abstract] [Full Text] [Related]
28. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. Ruilope L. J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516 [Abstract] [Full Text] [Related]
29. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Karlberg BE, Lins LE, Hermansson K. J Hypertens; 1999 Feb; 17(2):293-302. PubMed ID: 10067800 [Abstract] [Full Text] [Related]
30. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T. J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216 [Abstract] [Full Text] [Related]
31. Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project. Franchi F, Lazzeri C, Foschi M, Tosti-Guerra C, Barletta G. J Hum Hypertens; 2002 Aug; 16(8):597-604. PubMed ID: 12149667 [Abstract] [Full Text] [Related]
32. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG. Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237 [Abstract] [Full Text] [Related]
33. Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326 [Abstract] [Full Text] [Related]
34. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M. Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289 [Abstract] [Full Text] [Related]
35. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D. Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154 [Abstract] [Full Text] [Related]
36. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A. Hypertension; 2007 Feb 09; 49(2):276-84. PubMed ID: 17159081 [Abstract] [Full Text] [Related]
37. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Am J Nephrol; 2002 Feb 09; 22(4):356-62. PubMed ID: 12169868 [Abstract] [Full Text] [Related]
38. [Enalapril and irbesartan in treatment of patients with arterial hypertension]. Tashchuk VK, Ilashchuk TO. Lik Sprava; 2002 Feb 09; (3-4):114-6. PubMed ID: 12145874 [Abstract] [Full Text] [Related]
39. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. J Hypertens; 2001 Oct 09; 19(10):1855-60. PubMed ID: 11593107 [Abstract] [Full Text] [Related]
40. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Hope S, Brecher P, Chobanian AV. Am J Hypertens; 1999 Jan 09; 12(1 Pt 1):28-34. PubMed ID: 10075381 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]